NeuroPace: Regulatory Detour, AI Addition, and the Core Story Holds

NeuroPace’s second-quarter report carried a familiar headline — RNS revenue grew more than 20% — but the real news is how the company is navigating a regulatory surprise while layering in a new AI product. The IGE PMA supplement did not receive the initial approval management expected, yet the agency’s response was framed as a winding path, not a wall. Meanwhile, the launch of ECoG Assistant gives investors a fresh reason to believe the platform’s data moat is widening.

IGE Setback: A Regulatory Detour, Not a Dead End

The most consequential update came from the FDA’s communication about the supplemental PMA for expanded indication into idiopathic generalized epilepsy (IGE). As Joel Becker put it, “the FDA made clear that the agency's response was not a disapproval, and the process has remained highly interactive” — Joel Becker, Chief Executive Officer · 2026-08-11. The agency wants more information on clinical benefit across certain patient subgroups, including baseline GTC seizure frequency and the clinical meaningfulness of reducing GTC seizures. Management is using the Submission Issue Request (SIR) process to align on an amendment, with expectations of submitting the analysis and requesting the SIR meeting “over the next few weeks.”

This is not the first time investors have heard about the FDA’s appetite for additional context; the prior quarter’s call already described a productive mid‑cycle review. The difference now is the explicit rejection of the current submission — a binary event that had been largely de‑risked in prior messaging. The company’s tone remains cautiously constructive, and the clinical community’s reaction has been supportive. The NAUTILUS publication in Epilepsia provides an external validation that keeps the narrative alive. Still, the SIR meeting is a gating event that will determine whether the 180‑day clock resets or stays interactive.

We expect to go into the meeting... the purpose of the meeting is really to provide a forum for us to align with the agency on the specifics of what they're looking for and our plans for data and the reporting of that data with them.

For a stock that has already seen a 27% drawdown from its May high, the IGE timing is the pivotal overhang. The company did not change its long‑term growth framework for the core focal indication, but the incremental revenue from IGE remains absent from guidance until approval. As Patrick Williams said in the prior call, “we are anticipating a midyear approval” — Patrick F. Williams, Chief Financial Officer · 2026-05-12 — that timeline has now slipped and is the primary reason the stock has de‑rated.

ECoG Assistant: The AI Differentiator

While IGE waits, NeuroPace is pressing ahead with its own artificial‑intelligence narrative. The launch of ECoG Assistant, described as the “world's first AI algorithm-based tool in the neuromodulation space” — Joel Becker, Chief Executive Officer · 2026-08-11, is a strategically important move. The tool uses proprietary physician‑labeled data to help clinicians identify ECoGs of interest, review trends over time, and assess circadian patterns. Early field feedback is positive, with physicians using the insights to adjust medication timing and therapy settings. Management emphasized that the underlying dataset now includes more than 27 million intracranial EEG recordings, creating what they call a “data moat.”

This is a company‑unique theme — not a broad AI wave but a specific clinical workflow enhancement. It also aligns with the broader push toward personalized medicine and shows how the RNS platform’s diagnostic capability can be monetized indirectly through increased adoption. The launch is not yet separately monetized, but it supports the RNS revenue engine by making physicians more efficient. In the Q&A, Joel Becker noted that beyond unit volume there are other business models, but those are “further downstream.”

Financial Discipline and Back‑Half Confidence

Financially, the second quarter continued to demonstrate operating leverage. Total revenue of $22.8 million rose 17% year‑over‑year, with RNS revenue up 21.3%. Adjusted gross margin was 83.4%, down slightly from the unusually high 84.0% a year ago but still strong. The company raised its full‑year revenue guidance to $99.5–$101.5 million and tightened the adjusted EBITDA loss range to $7.5–$8.5 million. In the prepared remarks, Patrick Williams stated: “We now expect full year adjusted EBITDA loss to be between $7.5 million and $8.5 million, improved from our previous expectation” — Patrick Williams, Chief Financial Officer · 2026-08-11.

The gross margin trajectory remains one of the most impressive aspects of the story. Over the past six years, gross margin has climbed from the low 70s to the low 80s, driven by production volume gains and disciplined pricing. This supports the company’s path toward cash‑flow breakeven, which management reiterated for “exiting 2027.”

But the core question for the stock is whether the back‑half acceleration materializes. Management expects third‑quarter RNS growth to be similar to the first half’s ~20%, while the full‑year guide implies a step‑up to 21–23%. That confidence is built on patient pipeline strength and record active prescribers. The Epilepsy Centers adoption, combined with community expansion, provides multiple levers. Yet the IGE delay, which had been a key bull case, now hangs over the story.

In the prior call, Patrick conveyed conviction that the core business could deliver even without the new indication: “I have a lot of conviction around that. I believe that the 20% CAGRs that we talked about when it comes to RNS are achievable” — Patrick F. Williams, Chief Financial Officer · 2025-08-12. That message is unchanged today. The market will need to see steady execution and a clear regulatory timeline before re‑rating the stock.